The primary objective of this study was to verify the suitability of reference tissue-based quantification methods of the metabotropic glutamate receptor type 5 (mGluR 5 ) with [ 11 C]ABP688. This study presents in vivo (Positron Emission Tomography (PET)) and in vitro (autoradiography) measurements of mGluR 5 densities in the same rats and evaluates both noninvasive and blooddependent pharmacokinetic models for the quantification of [ 11 C]ABP688 binding. Eleven rats underwent [ 11 C]ABP688 PET scans. In five animals, baseline scans were compared with blockade experiments with the antagonist 1,2-methyl-6-(phenylethynyl)-pyridine (MPEP), and arterial blood samples were drawn and corrected for metabolites. Afterward, saturation-binding autoradiography was performed. Blocking with MPEP resulted in an average decrease of the total distribution volume (V T ) between 43% and 58% (thalamus and caudate-putamen, respectively) but had no significant effect on cerebellar V T (mean reduction: À0.01%). Comparing binding potential (BP ND ) based on the V T with noninvasively determined BP ND revealed an average negative bias of 0.7% in the caudateputamen and an average positive bias of 3.1% in the low-binding regions. Scan duration of 50 minutes is required. The cerebellum is a suitable reference region for the quantification of mGluR 5 availability as measured with [ 11 C]ABP688 PET in rats. Blood-based and reference region-based PET quantification shows a significant linear relationship to autoradiographic determinations.
Introduction
The metabotropic glutamate receptors (mGluRs) are G-protein-coupled receptors modulating synaptic transmission and neuronal excitability (for review see Cartmell and Schoepp, 2000) . A dysfunction of the mGluR has been implicated for various neurological and psychiatric disorders.
Group I mGluR (mGluR 1 and mGluR 5 ) participate in the neurotoxicity and over excitability during epileptogenesis. Agonists for group I mGluR induced an excessive phospoinositid turnover and acted as convulsives in rodents (Conn and Pin, 1997; Tizzano et al, 1995) . An upregulation of mGluR 5 was found in hippocampal specimens from patients suffering from pharmaco-resistant temporal lobe epilepsy (Notenboom et al, 2006) . Induced clonic seizures were suppressed by systemic application of mGluR 5 antagonists in mice (Chapman et al, 2000) .
Changes of the mGluR were found in neurodegenerative diseases like the dementia of the Alzheimer's type (for review see Parameshwaran et al, 2008) . Further, it has been shown that pharmacological blockade of mGluR 5 produces neuroprotection in a variety of models of neurodegeneration (for review see Bruno et al, 2001) .
Because of a high interest in modulating mGluR 5 activity, several drugs have been developed. Regarding Positron Emission Tomography (PET) imaging purposes, the currently most promising radiopharmaceutical is 3-(6-methyl-pyridin-2-ylethynyl)cyclohex-2-enone-O-11 C-methyloxime ([ 11 C]ABP688). In contrast with classic orthosteric receptor ligands, [ 11 C]ABP688 binds to the mGLUR 5 allosteric-binding site with high selectivity and high affinity (dissociation constant (K D ) = 2.3 nmol/L). It shows good blood-brain barrier permeability (extraction fraction B90%, logP = 2.4), fast kinetics, and nonbrain-permeable peripherally generated radioactive metabolites. [ 11 C]ABP688 has successfully been used for the quantification of mGluR 5 in rats and humans in vivo and in vitro (Ametamey et al, 2006 Hintermann et al, 2007; Wyss et al, 2007; Treyer et al, 2007) . However, the methods for quantification of receptor availability implemented so far were dependent on metabolitecorrected arterial blood samples as input function.
The purpose of this study was to evaluate the reference tissue methods for [ 11 C]ABP688 to circumvent invasive blood collection procedures in rats for quantifying receptor changes, which will permit repeated scans in the same animal.
Prerequisites for a tissue to be applicable as a reference region are the following: no specific binding in this region, identical nondisplaceable binding as in the target region, and localization behind the blood-brain barrier. Although the latter criteria are common for neuronal tissue, the first assumption is not fulfilled for the mGluR 5 in rats as has been shown repeatedly (Patel et al, 2007; Hintermann et al, 2007; Minuzzi et al, 2009 ). Nevertheless, the ratio of specific binding of target to reference region (8-to 28-fold, see Discussion) is huge. Together with a small ratio of specific binding in reference region to nondisplaceable binding, the specific fraction could be negligible.
The proposed methods were evaluated by invasive in vivo blocking experiments in control rats. The aim was to confirm autoradiographic evidence that the cerebellum of the rat is a suitable reference region for [ 11 C]ABP688 modeling.
In vivo binding experiments at tracer doses and blocking experiments were further verified by autoradiographic experiments in the same animals.
Materials and methods

Animals
Eleven male Sprague-Dawley rats (614±106 g) were used. Rats were housed in a 12-hour light/dark cycle at 211C, with access to food and water ad libitum; treatment was according to the Guide to the Care and Use of Experimental Animals (2nd edn) of the Canadian Council on Animal Care. The MicroPET imaging protocol was approved by the Animal Care Committee of the McGill University (Montreal, Quebec, Canada).
Five animals were used for baseline and subsequent blockade experiments, with arterial blood sampling of which four were included into autoradiographic evaluation. In addition, one animal without blood sampling underwent autoradiography.
Respiration rate, heart rate, and body temperature were monitored throughout the scan (MP150; Biopac Systems, Goleta, CA, USA).
Arterial Blood Sampling and Tracer Application
For the experiments without blood sampling, the radiotracer was administered as a 0.3-mL bolus injection over 5 seconds into the tail vein.
For the experiments with arterial blood samples, a polyethylene tube (PE50; Beckton Dickinson, Sparks, MD, USA) (catheter length: 10 cm, dead volume: 25 mL) was inserted into the femoral artery under general anesthesia with isoflurane. A venous catheter in the femoral vein served for tracer application. Surgery preceded the dynamic acquisitions by 1 hour. A syringe pump (model 33; Harvard Apparatus, Holliston, MA, USA) was used to infuse 1 mL of radiotracer over 90 seconds. The radioligand was diluted in 1 mL to reduce later fluid loss by blood sampling. Samples were collected by releasing the blockade of the catheter after discarding the dead volume of the catheter in heparin-coated microtubes by using a custom made three-way stopcock with a dead volume of 10 mL. To prevent coagulation and to substitute the loss of fluid, we flushed the catheter with heparinized saline solution after sampling. All whole blood and plasma samples were weighted to calculate the activity concentration. Targeted volume of whole blood samples was 100 to 150 mL per sample, which added up to 2.2±0.3 mL per experiment.
Samples were collected at 0.5, 1, 1.5, 2, 2.5, 3, 5, 10 minutes and in 10-minute intervals thereafter. An additional blood sample was taken before [ 11 C]ABP688 administration, which served for the assessment of the fraction of free tracer in plasma (i.e., unbound to plasma proteins; denoted by f P ). Individual f P values were determined by ultra filtration after incubation of whole blood samples with [ 11 C]ABP688.
Metabolite Correction
After quantifying the whole blood and plasma activity concentration, the fraction of intact radioligand of total plasma activity was determined as described earlier . Briefly, the intact ligand was bound by solid phase extraction to reversed phase C18 cartridges (Sep-Pak Plus; Waters Corporation, Milford, MA, USA). The cartridges were prewashed with 5 mL of water and flushed with the plasma sample diluted in 2.5 mL of water. Hydrophilic compounds were then eluted with 5 mL of water, and the cartridge was flushed with 10 mL of air to clear from fluid. The cartridge and a 1-mL fraction of the flushing fluid were then measured in the well counter. Metabolite analysis was performed for each blood sample. Previous test revealed that the retention of the parent compound in solvent to the cartridge (recovery factor) was between 91% and 96%. Therefore, the time course of the fraction of parent compound was normalized to the first sample and was fitted by nonlinear regression analyses (f(t) = 1/(1 + a Â t^b)^c + d). This fit was subsequently used to generate metabolite-corrected plasma curves. In the blocking experiment, radiolabeled metabolites from the preceding baseline experiment were already present in the first sample. Therefore, the recovery factor from the baseline experiment was used to correct for the incomplete retention of the cartridge.
Positron Emission Tomography Acquisition and Reconstruction
The PET measurements were performed on a Siemens MicroPET R4 scanner (Siemens-CTI, Knoxville, TN, USA), which has a spatial resolution at the center of the field of view of 1.84 mm full width at half maximum in the axial direction and 1.66 mm full width at half maximum in the radial and tangential directions (Knoess et al, 2003) . Animals lay in prone position with the head immobilized by both the body holder and the nose cone of the anesthesia system with 2% isoflurane at 0.5 L/min oxygen flow. The brain was positioned in the center of the field of view. A 10-minute 57 Co-transmission scan was acquired to correct for attenuation. Total acquisition time was 60 minutes.
List mode data were framed into a dynamic sequence of 12 Â 10 seconds, 3 Â 20 seconds, 3 Â 30 seconds, 3 Â 60 seconds, 3 Â 150 seconds, and 9 Â 300 seconds frames. Sixty-three slices of 1.2115-mm thickness (pixel size = 0.599891 Â 0.599891 mm 2 , 128 pixels) were reconstructed by filtered back projection (Ramp filter, cutoff = 0.5) after Fourier rebinning into 2D sinograms. Data sets were corrected for random coincidences, scatter radiation, and attenuation.
Image Analysis
Coregistration of an integrated image to a cryosectionbased rat template (Rubins et al, 2003) was performed manually by rigid body transformation based on anatomical landmarks using the software package PMOD (version 2.9; PMOD Group, Zurich, Switzerland, http://www. pmod.com). After checking for potential head movements, the transformation matrix was applied to each frame.
Regional time-activity curves (TACs) based on volumes of interest defined on the rat template were calculated for the following brain regions: cerebral cortex (mean total volume of left and right side = 0.79 mL), frontal/cingulate cortex (0.05 mL), hippocampus (0.178 mL), thalamus (0.124 mL), caudate-putamen (0.155 mL), and cerebellum (0.244 mL). The defined regions were sized to cover the entire anatomical structure.
Kinetic Models
Although receptor density is the parameter of interest, the maximal number of receptors available for binding (B avail ) cannot be determined in a single injection PET study. Therefore, the outcome parameters that are directly proportional to B avail have been proposed: equilibrium total distribution volume (V T ) and binding potential (BP ND ) (Innis et al, 2007) . The V T is composed of the specific distribution volume (V S , equal to f P B avail /K D ) and the distribution volume of free and nonspecifically bound ligand (V ND ). While V T is dependent on blood sampling, BP ND refers to a region without or negligible specific binding. Herein, the ratio of V T /V ND À1 is also linearly related to B avail . The cerebellar cortex is used as reference region for [ 11 C]ABP688 PET. The V T was determined by the following models: (1) standard two-tissue compartment model (2TCM) with blood volume fixed at 0.03 mL/cm 3 (Adam et al, 2003) (2TCM); (2) as proposed by Wyss et al for [ 11 C]ABP688 the 2TCM with fixed values (determined by coupled fitting for all regions) for K 1 /k 2 and k 4 ; and (3) Logan's graphical analysis (GA) with a time of linearization t* = 10 minutes (Logan et al, 1990) . The arterial input function was shifted relative to the brain tissue response because of the time delay imposed by the length of catheter used for blood sampling. The delay was fitted previous to the modeling and kept fixed for the further analyses.
The BP ND was determined by the following methods: (1) calculating the distribution volume ratio from the 2TCM (Mintun et al, 1984) ; (2) the simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996) ; (3) its two-step simplified version (SRTM2) (Wu and Carson, 2002) ; (4) multilinear reference tissue model (MRTM) (Ichise et al, 2003) ; (5) its two-parameter version (MRTM2) (Ichise et al, 2003) ; and (6) noninvasive Logan's GA (NIGA) with a t* = 10 minutes (Logan et al, 1996) . Selection of t* was based on visual inspection of the residual plot. If the model was dependent on a predetermined k 2 0 , the average of low-noise regions from the SRTM/MRTM was used (Ichise et al, 2003) . For MRTM2, different t* (0, 13, and 30 minutes) were evaluated for its bias compared with the BP ND calculated using 2TCM V T . This was necessary as the reference region was best fitted by a 2TCM, which violates in a strict sense the use of t* = 0 minute. Parametric images were generated representing V T by the GA and BP ND and R 1 (ratio of ligand delivery to target and reference region) by the MRTM2 model.
The Akaike Information Criteria were used to assess the goodness-of-fit with a penalty for increasing the number of parameters in the model.
Time Stability
To test the dependency of the different methods of quantification of the scanning time, the stability and accuracy were analyzed by repeating the process with shortened scan durations in steps of 5 minutes (i.e., by iteratively omitting the last PET frames). The outcome parameters were normalized to the value obtained from the 60 minutes scan analysis for all scans with blood sampling.
Blocking Experiments
To evaluate cerebellum as a possible reference region, the specific binding was blocked after a baseline scan by the antagonist 1,2-methyl-6-(phenylethynyl)-pyridine (MPEP). It was administered by slow intravenously infusion directly after the first scan with a dose of 6 mg/kg body weight in a 10 À2 mol/L saline solution. The blockade scan was started on average 18±10 minutes after infusion of MPEP, which resulted in an average time difference of 78 minutes between first and second [ 11 C]ABP688 injection. We did not observe any alterations of the physiological parameters monitored. [ 11 C]ABP688 was synthesized by reacting the sodium salt of desmethyl-ABP688 (ABX (Radeberg, Germany) desmethyl-ABP688 with NaOH) in anhydrous dimethylsulfoxide with [ 11 C]methyl iodide at 901C for 5 minutes. The product was purified by semipreparative high-performance liquid chromatography (Waters, mBondapak, C18; mobile phase, acetonitrile: 0.1% phosphoric acid (30:70); flow rate, 2 mL/min), and the retention time was 10 minutes. After removal of the high-performance liquid chromatography solvent by evaporation, the product was formulated using 9 mL of phosphate buffer and 1 mL EtOH. TLC: CH2Cl2:MeOH:AOAc (7:2:1). The radiochemical purity was > 99%.
Radioligands and Chemicals
For the blockade experiments at the start of the first scan, the mean specific radioactivity was 5.2 ± 4 GBq/mmol (range = 1.7 to 9.9 GBq/mmol) and 0.39±0.36 GBq/mmol (range = 0.1 to 1.0 GBq/mmol) at the second scan. The mean injected radioactivity at first scan was 17.3 ± 6.6 MBq (range = 8.9 to 25.3 MBq) and at second scan was 9.3 ± 3.9 MBq (range = 6 to 13 MBq). The mass of injected ABP688 per body weight at first scan was 7.8 ± 5.9 nmol/kg (range = 3.5 to 17.8 nmol/kg) and at second scan was 61.1 ± 35.3 nmol/kg (range = 12.8 to 109.2 nmol/kg).
For the experiments used for the noninvasive modeling, the mean specific radioactivity was 6.4±3.8 GBq/mmol (range = 1.7 to 13.8 GBq/mmol). The Mean injected radioactivity was 14 ± 6.6 MBq (range = 3.9 to 25.3 MBq), and the mass 4.9 ± 4.was 3 nmol/kg (range = 1.7 to 17.8 nmol/kg).
Autoradiography
Rats (n = 5) were decapitated, their brains rapidly removed, frozen in 2-methylbutane (À401C), and stored at À801C. Ten brain sections per rat (20 mm thick) were thaw mounted onto poly-L-lysine-coated slides and stored at À801C. After a preincubation in N 2 Hepes buffer (30 mmol/L; pH 7.4 containing 40 mmol/L NaCl, 5 mmol/L KCl, 2.5 mmol/L CaCl 2 and 1.2 mmol/L MgCl) for 15 minutes at room temperature, 10 sections per rat were incubated (65 minutes; room temperature) in buffer containing seven different concentrations of [ 3 H]ABP688. For the assessment of nonspecific binding, three slices per section were incubated with MPEP (10 mmol/L) in the medium. After three washes in incubation buffer (5 minutes, 41C) and a rapid rinse in ice-cold water (15 seconds), the sections were dried with a stream of air (room temperature). Sections were then dried further in a vacuum container with formaldehyde powder for mild fixation (20 hours). Specific binding was calculated as the difference of total and nonspecific binding. Labeled sections were placed on phosphor-imaging plates (BAS 2025; Fuji, Japan), with industrial tritium activity standards (Amersham Biosciences, Piscataway, NJ, USA). On exposure, the plates were scanned with a plate reader (spatial resolution of 50 mm; BAS 5000; Fuji). The digital receptor autoradiography was processed using image analysis software (Image Gauge 4.0; Fuji) defining regions of interest (ROIs) according to a standard rat brain atlas (Paxinos and Watson, 1998) on each of the 10 sections per brain processed. The average area covered by the ROI were cerebellum 35.7 mm 2 ; frontal/cingulate cortex 5.4 mm 2 ; cortex 50.2 mm 2 ; hippocampus (left and right) 5.6 mm 2 ; thalamus 18.8 mm 2 ; caudate-putamen (left and right) 10.9 mm 2 .
Statistics
All reported average values are mean±s.d. Comparison of imaging outcomes across brain regions were conducted using one-way repeated analysis of variance followed by pairwise comparison corrected for multiple testing according to Bonferroni. Pearson's product-moment correlation coefficient and linear regression were conducted using SPSS (version 11.5; SPSS Inc., Chicago, IL, USA). Figure 1A) . The TACs of the plasma concentration of the parent compound and the fraction of metabolites are shown in Figure 1B . Ligand concentrations increased in plasma and tissue linearly until the pump stopped after 90 seconds and decreased rapidly thereafter. No metabolism of [ 11 C]ABP688 could be observed up to 60 seconds after injection. Parent compound was reduced to a fraction of 0.5 after B5 minutes and to 0.14 ± 0.03 after 60 minutes in the baseline and to 0.5 after 12 minutes and 0.25±0.08 in the blockade experiment. The fraction of intact ligand in the blockade experiment amounted in the first samples after injection only to 0.91 ± 0.03 because of the presence of metabolites from the previous baseline experiment. Metabolite data could well be fitted by the equation proposed in the Materials and methods section. The ratio of plasma to whole blood activity peaked after 2 minutes (1.39 ± 0.13) and reached a steady state after 20 minutes being 1.10 ± 0.07 in baseline and 1.18±0.08 after blockade. Plasma free fraction was on average 14.4%±5.6%. Figures 2A and 3 depict the typical distribution of mGluR 5 in the rat brain, which is in good accordance to the distribution pattern in autoradiography ( Figure  2C ) of the same animal and of studies using different ligands (Patel et al, 2007) .
Results
Metabolite-Corrected Plasma Kinetic Analyses: Baseline and Blocking Experiments
The 2TCM without fixing K 1 /k 2 and k 4 or only k 4 showed superior fitting compared with 2TCM with constraints as judged by lower values of the Akaike Information Criteria in all regions. Therefore, the standard 2TCM was used for all subsequent analyses.
The results of the 2TCM fits are summarized in Table 1 . The estimated K 1 values are high (0.8 to 1.3 mL per cm 3 per minute), which is in agreement with the reported high extraction fraction of over of [ 11 C]ABP688, and the literature values reported for regional cerebral blood flow of rats was in the range of 1.3 to 1.7 mL per cm 3 per minute (Adam et al, 2003) . The percent standard error of estimation of the parameter fits ranged for K 1 between 1.7% to 6.5%, k 2 4.6% to 14%, k 3 6.1% to 23% and k 4 4.3% to 26%, being highest for K 1 and k 2 in the smallest ROI (frontal) and for k 3 and k 4 in cerebellum (exceeding 10% only there). The V T based on the 2TCM was highest in caudate-putamen (8.5 mL/cm 3 ) and lowest in cerebellum (2.6 mL/cm 3 ). We found no relation between the injected dose and the V T . The GA revealed V T estimates in excellent agreement with the 2TCM V T (R 2 = 0.999: the correlation graph and the regression term are provided in Figure 4A ).
Blocking the binding site with MPEP resulted in an average decrease of binding between 43% and 58% (thalamus and caudate-putamen, respectively) when analyzed with 2TCM. In the cerebellum, no reduction of V T (À0.01% on average) could be observed, which was significantly different from zero. The GA showed a nonsignificant reduction of 7% (P = 0.38).
Reference Tissue-Based Kinetic Analyses
As there was no effect of the blockade detectable in the 2TCM V T of cerebellum, this region was chosen as reference region for testing the noninvasive quantification. Although, cerebellar kinetics could not be described adequately with a 1TCM (which is a violation of the assumptions of the SRTM), this model with cerebellar input was able to successfully quantify the binding of the radiotracer. Comparing BP ND based on the 2TCM with SRTM BP ND (correlation sketch: Figure 4B ) revealed an average negative bias of 0.7% in the caudate-putamen (maximum 10%) and an average positive bias of 3.1% (maximum: 30%) in the low-binding region thalamus likely due to the required two-tissue kinetics in cerebellum . This bias was less pronounced when compared with the MRTM2 ( Figure 4D ) and least compared with the NIGA (Figure 4C ). The correlation within the reference models itself was excellent and without noticeable bias (data not shown). Delaying t* of the MRTM/ MRTM2 from 0 to 13 and 30 minutes did not reduce the observed bias to the BP ND based on the 2TCM but increased the noise in the correlation analysis substantially (2TCM BP ND versus MRTM2: 0 minutes: y = 0.85x + 0.27, R 2 = 0.98; 13 minutes: y = 0.82x + 0.32, R 2 = 0.95; 30 minutes: y = 0.81x + 0.26, R 2 = 0.81). Therefore, we decided to fix t* to 0 minute, which enables to calculate the ratio of ligand delivery to target and reference region (R 1 ).
The BP ND values at baseline and blockade condition are summarized in Table 2 . Blockade resulted in an average decrease of binding between 65% and 87% (thalamus and hippocampus, respectively) when analyzed with MRTM2 and between 77% and 87% for 2TCM-based BP ND . in terms of bias and variance. Thus, 60 minutes of dynamic data are suitable for the quantitative assessment of mGluR 5 . When scan duration is shortened to 30 minutes instead modeling becomes unstable and is associated with an average bias of À2% to À6% ( Figure 4E ). Figure 3A illustrates averaged (n = 11) parametric images of BP ND generated with voxel-wise application of the MRTM2. Corresponding relative blood flow maps can be found in Figure 3B . The MRTM2 could be used successfully in all animals, in contrast to parametric images based on NIGA or SRTM, which were associated with considerable noise and several voxels where the modeling failed (data not shown). The BP ND values read out using the same ROI as for TAC generation showed excellent congruency without any bias (regression: y = 1.0098x + 0.0014, R 2 = 0.999, P < 0.0001) for the ROI TAC-based MRTM2 and the voxel-wise parametric image. Figure 2A shows a representative example of a parametric image of V T generated with GA. The V T values read out using the same ROI as for TAC generation revealed a consistent negative bias (6% for high-binding region, considerably less for low binding. Regression: y = 0.9371x to 0.0383, R 2 = 0.99, P < 0.0001) of the voxel-wise GA compared with the 2TCM and GA.
Time Stability of Parameter Estimation
Parametric Images
Autoradiography and Saturation Binding
[ 3 H]ABP688 binding in the rat brain was saturable and the nonlinear fit to the one binding site model revealed B max values between 80 and 2300 fmol/mg (tissue) (cerebellum and caudate-putamen, respectively) and K D values between 1.1 and 6 nmol/L (across animals). Average regional results are provided in Table 3 , and a saturation-binding curve is presented in Figure 2E . The near to identity slope of the data transformed to the Hill plot of on average 0.98±0.03 confirmed the use of a single site binding model. Saturable binding was also detected in white matter tissue. The mean B max value in white matter was 171±21 fmol/mg (tissue) and K D value was 2.45 ± 1.1 nmol/L.
Comparing K D differences over brain regions by performing a repeated-measures analysis of variance revealed a significant difference only for the contrast caudate-putamen versus cortex (P = 0.006).
In Vivo-In Vitro Comparison
A significant relationship was observed between PET and autoradiographic measures in the same animals. Correlation between V T and B max is displayed in Figure 5A (Pearson's correlation P < 0.0001, regression data provided in the figure) and between BP ND and B max in Figure 5B (P < 0.0001).
In autoradiography, total binding was reduced in the presence of the competitor MPEP in the 8 nmol/L [ 3 H]ABP688 assay by 75% to 92% in the high-binding regions and by 48% in the cerebellum (Table 3) . GA, graphical analysis; MPEP, 1,2-methyl-6-(phenylethynyl)-pyridine; V T , total distribution volume; 2TCM, two-tissue compartment model. The effect of MPEP blockade on distribution volume (V T ) is not present in the cerebellum (n = 5).
[ 11 C]ABP688 reference models validation D Elmenhorst et al Comparing these relative in vitro changes to the ones in vivo shows a good correlation to the reduction in BP ND (MRTM2, y = 0.76x to 0.25, R 2 = 0.97) and a moderate to the decrease in V T (without cerebellum, y = 0.75x to 0.5, R 2 = 0.62).
Discussion
This study presents in vivo and in vitro measurements of mGluR 5 in the same rats and evaluates metabolite-corrected plasma input function and reference tissue-based pharmacokinetic models for the quantification of the PET radiotracer [ 11 C]ABP688.
The primary objective of this study was to evaluate whether reference tissue methods provides suitable measures of mGluR 5 availability in the rat brain. The line of evidence that leads to the conclusion that the cerebellum is a suitable reference region for reference tissue models is based on the following four major points: (1) there is no displaceable binding in the proposed reference region; (2) blood input-based quantification is correlated to reference region-based input quantification; (3) PET quantification correlates with autoradiographic quantification; and (4) the level of nondisplaceable uptake in the reference region and the ROI is the same. The conclusions were drawn from the experimental data by showing that (1) the blockade of binding had a negligible effect on cerebellar V T , (2) the good correlation of 2TCM BP ND to reference model BP ND , (3) the good correlation of BP ND to B max , and (4) the linearity of the Lassen plot of occupancy.
In detail, this was shown in vivo by comparing baseline scans to blockade experiments with a high dose of the selective antagonist MPEP and unlabelled ABP688 (due to the injection of the radiotracer with a low-specific activity). Blockade had no effect on cerebellar V T estimated with the 2TCM. The cerebellum is therefore considered as a suitable reference region, which can be applied with various noninvasive methods.
The bias between reference models BP ND to 2TCM BP ND due to the nonunity of the correlations was most pronounced in the SRTM in the low-binding region thalamus but low with a positive average bias of 3.1%. This nonunity and the magnitude of the bias have been observed for several other PET ligands that are quantified with a reference models Gallezot et al, 2010) . The relationship between BP ND and V T was though linear and thus provides as well a linear estimate of receptor density as can be seen in the linear correlation to the autoradiography B max .
In the autoradiographic saturation-binding experiments of the animals, which were previously scanned with PET, specific binding was detectable in cerebellum (B90 fmol/mg (tissue)). This was expected as immunohistochemical investigations found antibody binding on glial cells like astrocytes (GFAP-positive cells) and oligodendrocytes (CNPasepositive cells) (Mudo et al, 2007) . In addition, mGluR 5 were found on Golgi cells of the granular layer (Neki et al, 1996) . Hintermann et al (2007) reported a rat whole brain homogenate binding of a B avail of 0.87 pmol/mg (protein) and a K D of 2.3 nmol/L for [ 3 H]ABP688. Tissue section experiments were only performed with a single concentration assay (5 nmol/L); therefore, only a caudate-putamen to cerebellum ratio (of about 8) can be calculated for comparison.
Specific binding in a saturation-binding experiment with [ 18 F]F-PEB (an analog of MPEP) was also found by Patel et al (2007) in rat cerebellum sections. Caudate-putamen to cerebellum ratio for [ 18 F]F-PEB in rats was about 28-fold with a B max of 1.4 nmol/L (tissue) in cerebellum.
Accordingly in this study, specific binding with a B max of 90 fmol/mg (tissue) was detected in cerebellar cortex and about twofold higher in white matter. B max was small in comparison to the high-binding regions (1400 fmol/mg (tissue)). The caudate-putamen to cerebellum ratio is about 16-fold in this assay. Nevertheless, transferring the in vitro finding to the PET experiment, where nondisplaceable binding is present, the fraction of specific binding in cerebellum can be estimated to be around 10% (assuming that V ND is homogenous). Because of the noise level in this low-binding region and a substantial partial volume effect, the impact of the in vivo blockade could be below the sensitivity of this experimental design. This question could be addressed by testretest evaluations. Spill in from tissue with non- [ 11 C]ABP688 reference models validation D Elmenhorst et al specific binding into a region with a small fraction of specific binding will seemingly reduce this fraction and eventually diminish possibly detectable differences in V T . In addition, it is very likely that in the in vivo situation not all receptors are as available for binding as in the autoradiography. Alternatively, one might say that, in vivo conditions, the cerebellum mGluR 5 is insensitive to displacement due to unavailability of allosteric-binding site. In fact, here we show evidence that cerebellar receptors might have different binding properties compared with the prosencephalic mGluR 5 . The V T after blockade is higher in caudateputamen than the V T in cerebellum (both, before and after blockade). This discrepancy can be explained by an incomplete blockade of the receptors. When the difference of V T in baseline and blockade experiment is plotted against V T of the baseline, the relationship should be linear, and the intercept with the x axis should give an estimate of the V ND and the slope of the regression should give an estimate of the occupancy (Lassen et al, 1995) . Applying this method to the averaged regional 2TCM data from Table 1 reveals about 85% blockade and a V ND of 2.7 mL/cm 3 (regression: y = 0.85x to 2.26, R 2 = 0.99, P < 0.0001). This V ND is higher than the cerebellar V T (2.6 mL/cm 3 ), which is proposed here as V ND . The difference is probably due to a more pronounced partial volume effect in this ROI on the outer surface compared with the structures like caudate-putamen, which are surrounded by receptor bearing tissue.
We were able to reproduce the previously published distribution pattern of [ 11 C]ABP688 and [ 3 H]ABP688 binding in rats. Although the V T in caudate-putamen found by Wyss et al (2007) were B1.8-fold higher for the baseline experiments (n = 9) and 1.3-fold higher for the blocking experiment (n = 1), these higher V T can be explained by substantial methodological differences to our approach: Wyss et al (2007) used a b probe placed in the rat caudate-putamen to acquire tissue TACs and used whole blood TACs measured continuously with a coincidence counter over 30 minutes. Whole blood activity was then converted with population-based and -fitted metabolite data from earlier experiments to estimate parent compound in plasma. Besides the differences in sensitivity and in partial volume effects between b probe and MicroPET, and besides possible spillover from blood vessels to the b probe etc. and the use of population-based metabolite correction instead of individual data or the age of the rats there are the following two major issues that influence the results. First, we found that at least 50 minutes of scanning are necessary to achieve stable fitting results for the 2TCM, and second, that MPEP impairs the metabolism of [ 11 C]ABP688 significantly and substantially at high doses. The measured metabolite fraction after blockade was up to two times higher than at the baseline condition. In addition, the determination of metabolites in every blood sample revealed that first metabolites were detected after 1.5 to 2 minutes, which implicates that the use of an exponential function for fitting without a delay overestimates metabolism during this time period.
The correlation of in vivo determinations of V T and BP ND versus the in vitro B max ( Figure 5 ) offers the possibility to approximate an in vivo K D (named K D app ): The intercept of V T versus B max should be V ND and the slope be f P over K D app times a partial volume effect factor. The intercept is with 2.59 mL/cm 3 very close to the 2TCM V ND of 2.56 mL/cm 3 . With the measured f P of 0.15 and the slope of 0.0039 L/nmol K D app is 38 nmol/L times the partial volume effect factor. If the caudate-putamen region from the atlas is filtered by a 2-mm Gaussian kernel, the partial volume effect factor is 0.55. This partial volume effect assumption would give an K D app of 19 nmol/L. Moreover, the intercept of BP ND versus B max should be zero and the slope be the free fraction of ligand in the nondisplaceable tissue compartment (f ND ) over K D app times the same partial volume effect factor. The fit of Figure 5B was close to zero with 0.25. If the fit is further forced to go through zero, the slope is 0.0014 L/nmol. The f ND should equal f P over V ND . B Figure 5 Comparison of metabotropic glutamate receptor type 5 (mGluR 5 ) concentrations in six brain regions measured with autoradiographic saturation-binding experiments (B max ) and positron emission tomography. Both total distribution volume (V T ) of the two-tissue compartment model (2TCM; n = 4) (A) and binding potential (BP ND ) (B) derived from the twoparameter version of the multilinear reference tissue model (MRTM2; n = 5) were highly correlated with B max . The solid line represents linear regression analysis. Results of regression are given.
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Using these values, an K D app of 22 nmol/L can now be calculated. In addition, the ratio of the two slopes should be f P over f ND and again give an estimate of V ND . This ratio of 2.78 is about 7% higher than the 2TCM V ND of 2.6 mL/cm 3 .
An important issue is whether the experiments were performed at tracer doses. To evaluate this question, we performed the following estimations: the plasma activity level of ABP688 in the latter half of the scans (C P , 30 to 60 minutes p.i. when high binding to reference region ratio was relatively stable Marner et al, 2010) is used as a measure of free ligand in plasma C FP = C P /SA Â f P (specific activity (SA)) and the assumption is made that C FP and C FT (the concentration of free ligand in tissue) have equilibrated during this time span (with certain restrictions as discussed in Innis et al (2007) ). The in vitro K D (2.2 nmol/L) was determined in saturation-binding experiments, and the occupancy can be estimated according to the Michaelis-Menten equation: Occ = C FT /(C FT + K D ) (Marner et al, 2010) . Under these assumptions, receptor occupancies with ABP688 were 2.5% ± 2.4% for the experiments with blood sampling (n = 5). Alternatively, the occupancy was estimated based on the peak uptake value in a reference region, the fraction of unbound tracer in tissue f ND = f P /V ND (Innis et al, 2007) and the in vivo K D app calculated of the slope of the correlation of autoradiography and PET (Gallezot et al, 2010) . The limit of injected dose was calculated to occupy < 5% of the receptors. For this study, the average cerebellum peak activity was 18.3 KBq/mL and the injected dose was 17.3 MBq, resulting in an average peak uptake value of 1.05 injected dose per liter. Together with the f ND based on the measured f P and the in vivo K D app , which was approximated from the correlation of V T and BP ND versus B max , the dose limit can be estimated to be 18 nmol. The highest dose injected in this study was 13 nmol.
In an earlier study, no effect of injected masses of up to 4.5 nmol/kg ABP688 on rat V T could be detected , which is close to the average injected mass in this experiment (4.9 nmol/ kg). However, a concluding answer to the occupancy issue can only be given by a dosing experiment.
A general restriction of reference tissue models is the homogeneity criterion of V ND , which makes the results prone to changes only in the reference region. Cerebellar diseases in particular atrophies or vascular diseases may invalidate the V ND estimation and comparability. When changes in cerebellar V ND cannot be ruled out, invasive quantification methods should be preferred.
In the human cerebellum, mGluR 5 densities and affinity are comparable to those in the rat cerebellum, and the high-binding region to cerebellum density ratio is similar as well ([ 3 H]ABP688 autoradiography of human hippocampus specimen 1300 and cerebellum 90 fmol/mg (tissue) (Minuzzi et al, 2009 ). Human [ 11 C]ABP688 PET V T cerebellum: 2.9, putamen 6.6 mL/cm 3 ). Animal models displaying the same receptor concentrations as humans, identical drug metabolism and pharmacokinetic profile can provide reasonable approximation of assumptions underlying the validity of reference regions in humans.
Thus, similarities in mGluR 5 binding between the species make it most probable that the human cerebellum could be used as a reference region as well, which would simplify the applicability of [ 11 C]ABP688.
Conclusion
The cerebellum is a suitable reference region for the quantification of mGluR 5 availability with [ 11 C]ABP688 PET in rats. Blood-based and reference region-based PET quantification is strongly supported by the in vitro autoradiographic determinations. A scan duration of at least 50 minutes is required.
